For inpatients with intracranial metastatic disease burden exceeding established SRS guidelines, BED-comparable short-course WBRT administered to 23 Gy in 5 fractions (4.6 Gy/fraction) is safe and efficacious. Given previous literature indicating that nearly half of the patients prescribed traditional 2-week WBRT die without completing treatment, BED-comparable WBRT represents an attractive and promising WBRT alternative in this patient population.
Keyphrases
- brain metastases
- small cell lung cancer
- squamous cell carcinoma
- end stage renal disease
- ejection fraction
- systematic review
- chronic kidney disease
- case report
- prognostic factors
- randomized controlled trial
- clinical trial
- optic nerve
- risk factors
- resting state
- patient reported outcomes
- patient reported
- optical coherence tomography
- placebo controlled